Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Darolutamide
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Orion's Partner Bayer Submits Darolutamide Application in China for Third Indication
Details : Nubeqa (darolutamide) is an orally available androgen receptor inhibitors, which is currently being evaluated for the treatment of metastatic hormone-sensitive prostate cancer.
Product Name : Nubeqa
Product Type : HPAPI
Upfront Cash : Inapplicable
January 07, 2025
Lead Product(s) : Darolutamide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Darolutamide
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Orion's Partner Bayer Submits Darolutamide Application in EU for Third Indication
Details : Nubeqa (darolutamide) is an orally available androgen receptor inhibitors, which is currently being evaluated for the treatment of metastatic hormone-sensitive prostate cancer.
Product Name : Nubeqa
Product Type : HPAPI
Upfront Cash : Inapplicable
October 14, 2024
Lead Product(s) : Darolutamide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Darolutamide
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Bayer Seeks U.S. FDA Nod for Third Indication of Orion-Originated Darolutamide
Details : Nubeqa (darolutamide) is an orally available androgen receptor inhibitors, which is currently being evaluated for the treatment of metastatic hormone-sensitive prostate cancer.
Product Name : Nubeqa
Product Type : HPAPI
Upfront Cash : Inapplicable
September 26, 2024
Lead Product(s) : Darolutamide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Darolutamide
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase III ARANOTE Trial in Prostate Cancer Meets Primary Endpoint
Details : Nubeqa (darolutamide) is an orally available androgen receptor inhibitors, which is currently being evaluated for the treatment of metastatic hormone-sensitive prostate cancer.
Product Name : Nubeqa
Product Type : HPAPI
Upfront Cash : Inapplicable
July 17, 2024
Lead Product(s) : Darolutamide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Opevesostat,Dexamethasone,Fludrocortisone Acetate
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Orion and MSD Initiate Two Phase 3 Trials Of ODM-208 in Prostate Cancer
Details : ODM-208/MK5684, a CYP11A1 inhibitor, is in Phase 3 trials for metastatic castration-resistant prostate cancer with hormone replacement.
Product Name : ODM-208
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 01, 2024
Lead Product(s) : Opevesostat,Dexamethasone,Fludrocortisone Acetate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Opevesostat,Dexamethasone,Fludrocortisone Acetate
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Merck & Co
Deal Size : $1,920.0 million
Deal Type : Licensing Agreement
Merck and Orion Mutual Option Exercise for Opevesostat in Prostate Cancer Treatment
Details : Through the license agreement, Merck will gain global rights to develop and commercialize MK-5684 (opevesostat), which is being evaluated for metastatic castration-resistant prostate cancer.
Product Name : MK-5684
Product Type : Other Small Molecule
Upfront Cash : $290.0 million
January 07, 2024
Lead Product(s) : Opevesostat,Dexamethasone,Fludrocortisone Acetate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Merck & Co
Deal Size : $1,920.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Opevesostat,Dexamethasone,Hydrocortisone
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 3 Clinical Trials with ODM-208 (MK-5684) posted to ClinicalTrials.gov Database
Details : ODM-208 (or MK-5684) is an investigational oral, non-steroidal and selective inhibitor of the CYP11A1 enzyme discovered and developed by Orion for the treatment of hormone-dependent cancers, such as metastatic castration-resistant prostate cancer.
Product Name : ODM-208
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 21, 2023
Lead Product(s) : Opevesostat,Dexamethasone,Hydrocortisone
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Darolutamide,Docetaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The sNDA is based on positive results from pivotal Phase III ARASENS trial demonstrating a statistically significant improvement in overall survival for Nubeqa (darolutamide) plus androgen deprivation therapy and docetaxel in men with mHSPC compared to A...
Product Name : Nubeqa
Product Type : HPAPI
Upfront Cash : Inapplicable
March 05, 2022
Lead Product(s) : Darolutamide,Docetaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Darolutamide,Docetaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The ARASENS trial, Nubeqa (darolutamide) in combination with docetaxel and androgen deprivation therapy significantly increased overall survival for patients with metastatic hormone-sensitive prostate cancer.
Product Name : Nubeqa
Product Type : HPAPI
Upfront Cash : Inapplicable
March 12, 2021
Lead Product(s) : Darolutamide,Docetaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Darolutamide
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Darolutamide significantly reduced risk of death by 31 percent in men with non-metastatic castration-resistant prostate cancer (nmCRPC).
Product Name : Nubeqa
Product Type : HPAPI
Upfront Cash : Inapplicable
May 14, 2020
Lead Product(s) : Darolutamide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
